-

Thermo Fisher Scientific Certifies Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System to Meet IVDR Requirements

Updated qPCR system now includes integrated software to support growing test menus for clinical laboratories and assay developers

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific has certified the Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System* to meet new In Vitro Medical Devices Regulation (IVDR) requirements. The updated system now includes new, complementary Applied Biosystems Diomni Software ecosystem to empower clinical labs and test developers to leverage flexible PCR testing onsite.

Designed for maximum productivity and fast ramp-up, the QuantStudio 7 Pro Dx Real-Time PCR System enables users to transition from development to validation on a single system. The expandable, automated platform comes with interchangeable 96-well and 384-well blocks and also includes remote desktop and touchscreen controls, facial authentication, voice command and smart tech support to increase user productivity.

“We have continued to support our customers throughout the transition to IVDR, first by introducing the updated Applied Biosystems QuantStudio 5 Dx Real-Time PCR System earlier this year and now with the launch of the IVDR-compliant QuantStudio 7 Pro Dx Real-Time PCR System and new complementary Diomni Software ecosystem,” said Fernando Beils, vice president and general manager of qPCR instruments at Thermo Fisher Scientific. “As test developers and laboratories expand their assay menus and IVD testing capabilities, we are committed to continue providing innovative solutions to meet their evolving needs.”

Whether performing a routine test or developing a new assay, the integrated, IVDR-compliant Applied Biosystems Diomni Software ecosystem is designed to streamline the entire workflow with a plug-and-play design and simplified set-up to enhance efficiency and minimize user error. The centralized set-up allows connection to multiple real-time PCR instruments and secure data sharing across a user network.

“The ability to import plate set-up files from external software and export result sets in a customizable structure made it easy to integrate the QuantStudio 7 Pro Dx Real-Time PCR System with our laboratory information management software,” said Dr. Gustav Quade, laboratory medicine and technical development specialist at the Quade Laboratory in Germany. “The new Diomni Software makes it easy to work collaboratively and we can set up runs, manage past runs and documentation, and interpret fluorescent curves remotely and efficiently without the need to install special software.”

The QuantStudio 7 Pro Dx Real-Time PCR System is available in all regions that recognize CE-IVD certification and is also listed with the U.S. Food and Drug Administration (FDA) as a class II medical device.

For more information, please visit www.thermofisher.com/quantstudio7prodx.

*The QuantStudio 7 Pro Dx Real-Time PCR System is For In Vitro Diagnostic Use.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

For more information, please visit www.thermofisher.com

Contacts

Media Contact Information:
Mauricio Minotta
Phone: 760-805-5266
Email: mauricio.minotta@thermofisher.com

Jennifer Heady
Phone: 413-237-5141
Email: jheady@greenough.biz

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)


Contacts

Media Contact Information:
Mauricio Minotta
Phone: 760-805-5266
Email: mauricio.minotta@thermofisher.com

Jennifer Heady
Phone: 413-237-5141
Email: jheady@greenough.biz

More News From Thermo Fisher

Thermo Fisher Scientific Reports First Quarter 2026 Results

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026. First Quarter Highlights First quarter revenue grew 6% to $11.01 billion. First quarter GAAP diluted earnings per share (EPS) grew 11% to $4.43. First quarter adjusted EPS grew 6% to $5.44. Delivered excellent performance in the first quarter, demonstrating the strength of our proven growth strategy, the...

Thermo Fisher Scientific Launches Applied Biosystems™ PowerFlex™ Thermal Cycler to Advance PCR Flexibility and Productivity

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Applied Biosystems™ PowerFlex™ Thermal Cycler, a next-generation polymerase chain reaction (PCR) instrument designed to help deliver enhanced flexibility, precise thermal performance and improved productivity for modern molecular biology laboratories. Building on the trusted legacy of Applied Biosystems™ instruments, this solution is designed to help laboratories run complex...

Thermo Fisher Scientific’s PPD Clinical Research Business Collaborates with HealthVerity to Expand Real-World Data Capabilities

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) marketplace, to enhance data-driven clinical development and evidence generation for biopharma sponsors. Through the agreement, Thermo Fisher’s PPD™ clinical research business will gain enterprise-level access to HealthVerity’s TaXOnomy® claims dataset, representing more than 270 million de-identified pa...
Back to Newsroom